S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
The Graphite Shortage Story You're Not Being Told (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Graphite Shortage Story You're Not Being Told (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Okta, Inc: When Great Results Aren’t Good Enough 
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
The Graphite Shortage Story You're Not Being Told (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Graphite Shortage Story You're Not Being Told (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Okta, Inc: When Great Results Aren’t Good Enough 
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
The Graphite Shortage Story You're Not Being Told (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Graphite Shortage Story You're Not Being Told (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Okta, Inc: When Great Results Aren’t Good Enough 
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
The Graphite Shortage Story You're Not Being Told (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Graphite Shortage Story You're Not Being Told (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Okta, Inc: When Great Results Aren’t Good Enough 
NASDAQ:UBX

Unity Biotechnology (UBX) Stock Forecast, Price & News

$3.18
+0.17 (+5.65%)
(As of 06/1/2023 ET)
Compare
Today's Range
$2.95
$3.32
50-Day Range
$1.49
$4.15
52-Week Range
$1.46
$18.50
Volume
277,704 shs
Average Volume
195,052 shs
Market Capitalization
$45.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75

Unity Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
112.3% Upside
$6.75 Price Target
Short Interest
Healthy
7.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
0.88mentions of Unity Biotechnology in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$15,097 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.41) to ($3.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

385th out of 1,980 stocks

Pharmaceutical Preparations Industry

157th out of 978 stocks


UBX stock logo

About Unity Biotechnology (NASDAQ:UBX) Stock

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.

Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

UBX Stock News Headlines

Wedbush Sticks to Its Buy Rating for Unity Biotechnology (UBX)
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
Unity Biotechnology (UBX) Gets a Buy from H.C. Wainwright
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Where Unity Biotechnology Stands With Analysts
Unity Biotechnology (UBX) Gets a Buy from Wedbush
Unity Biotechnology (UBX) Receives a Rating Update from a Top Analyst
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $5.00
Expert Ratings for Unity Biotechnology
See More Headlines

UBX Price History

UBX Company Calendar

Last Earnings
3/15/2023
Today
6/02/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:UBX
Fax
N/A
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.75
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+112.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-59,930,000.00
Pretax Margin
-21,981.78%

Debt

Sales & Book Value

Annual Sales
$240,000.00
Book Value
$4.08 per share

Miscellaneous

Free Float
13,848,000
Market Cap
$45.66 million
Optionable
Not Optionable
Beta
0.71

Key Executives

  • Anirvan Ghosh
    Chief Executive Officer & Director
  • Nathan Guz
    Vice President-Operations
  • Lynne Sullivan
    Chief Financial Officer
  • Przemyslaw Sapieha
    Chief Scientist
  • Alexander Nguyen
    Secretary & General Counsel













UBX Stock - Frequently Asked Questions

Should I buy or sell Unity Biotechnology stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UBX shares.
View UBX analyst ratings
or view top-rated stocks.

What is Unity Biotechnology's stock price forecast for 2023?

5 equities research analysts have issued 12-month price objectives for Unity Biotechnology's stock. Their UBX share price forecasts range from $5.00 to $10.00. On average, they expect the company's stock price to reach $6.75 in the next twelve months. This suggests a possible upside of 112.3% from the stock's current price.
View analysts price targets for UBX
or view top-rated stocks among Wall Street analysts.

How have UBX shares performed in 2023?

Unity Biotechnology's stock was trading at $2.74 at the beginning of the year. Since then, UBX stock has increased by 16.1% and is now trading at $3.18.
View the best growth stocks for 2023 here
.

Are investors shorting Unity Biotechnology?

Unity Biotechnology saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 952,200 shares, a decrease of 17.2% from the April 30th total of 1,150,000 shares. Based on an average trading volume of 417,800 shares, the short-interest ratio is presently 2.3 days. Approximately 7.4% of the shares of the company are sold short.
View Unity Biotechnology's Short Interest
.

When is Unity Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our UBX earnings forecast
.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) issued its earnings results on Wednesday, March, 15th. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.15.

When did Unity Biotechnology's stock split?

Unity Biotechnology shares reverse split on the morning of Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (2.01%), Geode Capital Management LLC (0.86%), BlackRock Inc. (0.75%), ExodusPoint Capital Management LP (0.65%), Renaissance Technologies LLC (0.54%) and Dimensional Fund Advisors LP (0.47%). Insiders that own company stock include Anirvan Ghosh, Jamie Dananberg and Nathaniel E David.
View institutional ownership trends
.

How do I buy shares of Unity Biotechnology?

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $3.18.

How much money does Unity Biotechnology make?

Unity Biotechnology (NASDAQ:UBX) has a market capitalization of $45.66 million and generates $240,000.00 in revenue each year. The company earns $-59,930,000.00 in net income (profit) each year or ($5.02) on an earnings per share basis.

How can I contact Unity Biotechnology?

The official website for the company is www.unitybiotechnology.com. The company can be reached via phone at (650) 416-1192 or via email at ir@unitybiotechnology.com.

This page (NASDAQ:UBX) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -